Jamaica’s outlook revised to stable by Fitch after hurricane
Investing.com - Piper Sandler has reiterated an Overweight rating and $93.00 price target on Structure Therapeutics (NASDAQ:GPCR), a $1.65 billion market cap clinical-stage biotechnology company. According to InvestingPro data, analyst consensus remains highly bullish with price targets ranging from $37 to $120, suggesting significant upside potential from the current $28.65 trading price.
The research firm believes now is an "opportune time" to own Structure Therapeutics shares ahead of Phase 2b ACCESS and ACCESS II trial readouts expected in early to mid-December 2025, which could validate the company’s lead drug candidate aleniglipron. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 20.48 and more cash than debt on its balance sheet, providing runway for its clinical programs.
Piper Sandler expressed confidence that the 120 mg dose of aleniglipron will achieve the benchmark of placebo-adjusted 10% weight loss at week 36 with favorable safety and tolerability, based on earlier Phase 2a efficacy data and the drug’s optimized titration scheme.
The firm noted that Structure Therapeutics stock sold off earlier this year due to a lack of near-term catalysts, but suggested that Eli Lilly’s upcoming Phase 3 ATTAIN-1 topline results for orforglipron in August 2025 has renewed interest in the space.
Structure Therapeutics is also advancing its amylin program with ACCG-2671 Phase 1 SAD/MAD initiation and a second amylin drug candidate selection expected by year-end 2025, while Piper Sandler believes strategic interest remains high given the current environment and recent transactions in the metabolic space. For deeper insights into Structure Therapeutics’ financial health, valuation metrics, and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Terns Pharmaceuticals has maintained its Market Outperform rating from Citizens, with a reiterated price target of $20.00. Citizens analyst Silvan Tuerkcan highlighted Terns’ unique positioning of its oral GLP-1 asset based on safety dynamics, and the company’s plans to seek partnerships following data release. Meanwhile, Structure Therapeutics has seen its stock rating reiterated at Buy by H.C. Wainwright, with a $60.00 price target, emphasizing its position in the oral weight loss drug market. Cantor Fitzgerald also reiterated an Overweight rating on Structure Therapeutics, setting a $65.00 price target and noting similarities between Structure’s aleniglipron and orforglipron. JMP Securities maintained its Market Outperform rating for Structure Therapeutics, citing positive safety data from a Phase 3 study of a similar compound, which bodes well for Structure’s aleniglipron. Cantor Fitzgerald mentioned a significant upcoming catalyst for Structure Therapeutics with Phase 2B obesity trial readouts expected by year-end 2025. These developments reflect the analysts’ continued confidence in the potential of both Terns Pharmaceuticals and Structure Therapeutics in their respective markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.